MedTrace Logo

Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli (EXPECT-1)

NCT04087681 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4479

Last updated 2021-09-21

No results posted yet for this study

Summary

The purpose of this study is to collect information from study participants who develop an invasive disease caused by Extraintestinal pathogenic E. coli (ExPEC) during a period of 12 months. This information will be used to support the development of a new vaccine to prevent ExPEC infections.

Conditions

  • E.Coli Infections

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    collaborator INDUSTRY

  • Innovative Medicines Initiative

    collaborator OTHER

  • MJM Bonten

    lead OTHER

Principal Investigators

  • Miquel Ekkelenkamp, Dr. · UMC Utrecht

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-28
Primary Completion
2021-05-07
Completion
2021-06-21

Countries

  • United States
  • Canada
  • France
  • Germany
  • Italy
  • Japan
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04087681 on ClinicalTrials.gov